CliffBio
biologic

Serostim

somatropin

Loss of exclusivityJuly 2009projected — 12-year biologic exclusivity estimate
CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand nameSerostim
Active ingredientsomatropin
Strength4MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 1997
Marketing statusRx

More from EMD Serono

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Serostim patent cliff — loss of exclusivity July 2009 | CliffBio